Sarepta Therapeutics (SRPT) Finished Goods (2016 - 2026)

Sarepta Therapeutics' Finished Goods history runs 11 years deep, the most recent figure standing at $58.0 million for Q1 2026.

• On a quarterly basis, Finished Goods fell 5.54% year-over-year to $58.0 million in Q1 2026; TTM through Mar 2026 was $58.0 million, a 5.54% decrease from a year earlier, with the FY2025 full-year figure at $65.3 million, up 38.36% from the prior year.
• Finished Goods retreated to $58.0 million in Q1 2026 per SRPT's latest filing, from $65.3 million in the prior quarter.
• Across five years, Finished Goods topped out at $78.0 million in Q3 2024 and bottomed at $33.9 million in Q1 2022.
• The 5-year median for Finished Goods is $49.3 million (2022), against an average of $52.6 million.
• Across the five-year window, Finished Goods surged 83.58% in 2022 and fell 23.62% in 2024, its largest moves.
• Year by year, Finished Goods stood at $38.1 million in 2022, then surged by 62.02% to $61.8 million in 2023, then decreased by 23.62% to $47.2 million in 2024, then soared by 38.36% to $65.3 million in 2025, then retreated by 11.24% to $58.0 million in 2026.
• Per Business Quant, the three latest SRPT Finished Goods figures stand at $58.0 million (Q1 2026), $65.3 million (Q4 2025), and $64.8 million (Q3 2025).